WS #16985
In the biotech sector, Ultragenyx announced that its Marketing Authorisation Application for an MPS IIIA gene therapy is under review by the UK MHRA, a positive catalyst for the rare disease space. Meanwhile, Citizens Financial Group reported Q3 results, though specific metrics were not detailed in the immediate stream. These developments are isolated from the broader macro sell-off, offering niche opportunities in defensive healthcare and financials.
Biotech and Financial Earnings
In the biotech sector, Ultragenyx announced that its Marketing Authorisation Application for an MPS IIIA gene therapy is under review by the UK MHRA, a positive catalyst for the rare disease space. Meanwhile, Citizens Financial Group reported Q3 results, though specific metrics were not detailed in the immediate stream. These developments are isolated from the broader macro sell-off, offering niche opportunities in defensive healthcare and financials.